CALT

15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)

SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)

SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

EFFECT - Calliditas Therapeutics AB (0001795579) (Filer)

SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in

25 - Calliditas Therapeutics AB (0001795579) (Filer)

S-8 POS - Calliditas Therapeutics AB (0001795579) (Filer)

S-8 POS - Calliditas Therapeutics AB (0001795579) (Filer)

POS AM - Calliditas Therapeutics AB (0001795579) (Filer)

SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)

SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

SC 14D9/A - Calliditas Therapeutics AB (0001795579) (Subject)

6-K - Calliditas Therapeutics AB (0001795579) (Filer)

SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire

STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light

6-K - Calliditas Therapeutics AB (0001795579) (Filer)

SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog

STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel

SC 14D9/A - Calliditas Therapeutics AB (0001795579) (Subject)